Recent Advances in the Study of 1-(2,3,5-Tri-O-acetyl-b-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic Acid Methyl Ester (CAS: 39925-10-5)
1-(2,3,5-Tri-O-acetyl-b-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic Acid Methyl Ester (CAS: 39925-10-5) is a key intermediate in the synthesis of nucleoside analogs, which have significant applications in antiviral and anticancer drug development. Recent studies have focused on optimizing its synthetic pathways, exploring its biological activities, and evaluating its potential as a precursor for novel therapeutic agents. This research brief consolidates the latest findings related to this compound, providing insights into its chemical properties, synthetic methodologies, and pharmacological potential.
A study published in the Journal of Medicinal Chemistry (2023) demonstrated the efficient synthesis of 1-(2,3,5-Tri-O-acetyl-b-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic Acid Methyl Ester via a modified Vorbruggen glycosylation reaction. The researchers achieved a yield of 78% by optimizing reaction conditions, including temperature, solvent system, and catalyst selection. The compound's purity was confirmed using HPLC and NMR spectroscopy, highlighting its suitability for further derivatization.
In terms of biological activity, recent in vitro studies have shown that derivatives of this compound exhibit promising inhibitory effects against RNA viruses, particularly SARS-CoV-2 and influenza A. The triazole moiety appears to play a crucial role in binding to viral polymerases, as revealed by molecular docking simulations. These findings, published in Antiviral Research (2024), suggest potential applications in developing broad-spectrum antiviral agents.
Another significant advancement comes from cancer research, where this compound has been used as a scaffold for developing novel kinase inhibitors. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that structural modifications at the triazole ring resulted in compounds with selective activity against EGFR-mutated cancer cell lines, with IC50 values in the low micromolar range.
The stability and pharmacokinetic properties of 1-(2,3,5-Tri-O-acetyl-b-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic Acid Methyl Ester have also been investigated. Recent ADME studies indicate that the acetyl groups provide improved membrane permeability compared to non-acetylated analogs, while the methyl ester moiety enhances metabolic stability. These characteristics make it a valuable intermediate for prodrug development, as discussed in a recent review in European Journal of Pharmaceutical Sciences (2024).
Looking forward, researchers are exploring novel enzymatic approaches for the synthesis of this compound, aiming to improve stereoselectivity and reduce environmental impact. Additionally, computational studies are being conducted to predict its interaction with various biological targets, which could accelerate the discovery of new therapeutic applications. The compound's versatility and the growing body of research surrounding it position 1-(2,3,5-Tri-O-acetyl-b-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic Acid Methyl Ester as a promising candidate for future drug development efforts in both antiviral and anticancer fields.
